Patents Assigned to Genentech
  • Publication number: 20130295007
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 30, 2013
    Publication date: November 7, 2013
    Applicant: GENENTECH, INC.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Patent number: 8574576
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: November 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Weilan Ye, Mark S. Dennis, Jill Fredrickson
  • Patent number: 8574869
    Abstract: Provided herein are methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: November 5, 2013
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Publication number: 20130287776
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: February 7, 2013
    Publication date: October 31, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Patent number: 8569281
    Abstract: The present invention relates to substituted pyrazolopyridine compounds, and pharmaceutically acceptable salts or esters thereof. The present invention further relates to therapeutic uses of pharmaceutical compositions comprising the substituted pyrazolopyridine compounds, for example, in cancer and neurodegenerative diseases.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: October 29, 2013
    Assignees: Medical Research Council Technology, Genentech, Inc.
    Inventors: Bryan K. Chan, Huifen Chen, Anthony Estrada, Daniel Shore, Zachary Sweeney, Edward Giles McIver
  • Publication number: 20130281432
    Abstract: Pyridone and pyrazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 31, 2011
    Publication date: October 24, 2013
    Applicants: GENENTECH, INC., GILEAD CONNECTICUT, INC.
    Inventors: Kevin S. Currie, Xiaojing Wang, Wendy B. Young
  • Patent number: 8562992
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
  • Patent number: 8563540
    Abstract: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Georgette Castanedo, Bryan Chan, Matthew C. Lucas, Brian Safina, Daniel P. Sutherlin, Zachary Sweeney
  • Patent number: 8563695
    Abstract: Compositions and methods are provided for the classification, diagnosis, treatment, and prevention of tumors characterized by loss of REST function, expression of ?2, and/or activation of Notch. Further compositions and methods are provided for modulation of cellular processes such as EMT, cell migration, and apoptosis.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Jing Li, Victoria Smith
  • Patent number: 8557768
    Abstract: The ?-subunit of human nerve growth factor (?NGF) is prepared in essentially pure form in commercially useful quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human ?NGF and host cells transformed with the vectors are also provided. The ?NGF which the invention provides is useful, for example, in treating nerve damage.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: October 15, 2013
    Assignee: Genentech, Inc.
    Inventors: Alane M. Gray, Axel Ullrich
  • Patent number: 8557967
    Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: October 15, 2013
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
  • Patent number: 8557238
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: October 15, 2013
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood
  • Publication number: 20130261103
    Abstract: Pyridazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 31, 2011
    Publication date: October 3, 2013
    Applicants: GENENTECH, INC., GILEAD CONNECTICUT, INC.
    Inventors: Kevin S. Currie, Xiaojing Wang, Wendy B. Young
  • Publication number: 20130261293
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: October 3, 2013
    Applicant: GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Publication number: 20130261104
    Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.
    Type: Application
    Filed: May 9, 2013
    Publication date: October 3, 2013
    Applicant: Genentech, Inc.
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
  • Publication number: 20130259867
    Abstract: The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 3, 2013
    Applicant: GENENTECH, INC.
    Inventors: Lukas Amler, David Shames
  • Patent number: 8545843
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 1, 2013
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Patent number: 8545850
    Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: October 1, 2013
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Publication number: 20130252934
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 26, 2013
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Publication number: 20130251720
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: October 9, 2012
    Publication date: September 26, 2013
    Applicant: GENENTECH, INC.
    Inventors: HILARY CLARK, DAN EATON, LINO GONZALEZ, JR., JANE GROGAN, JASON A. HACKNEY, KRISTIN HARDEN, XIN YU